MedTrace Logo

Efficacy and Safety of SR1375 in Adult Patients With CAP

NCT06577558 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2025-07-09

No results posted yet for this study

Summary

This is a phase 2 study to evaluate the efficacy and safety of SR1375 in hospitalized adult patients with CAP. Patients will receive SR1375 or placebo for 8 weeks. The study duration for each patient is up to 10 weeks.

Conditions

  • Community-acquired Pneumonia

Interventions

DRUG

SR1375 capsule 3mg+regular treatments

SR1375 capsule 3mg QD orally+CAP regular treatments

DRUG

SR1375 capsule 1mg+regular treatments

SR1375 capsule 1mg QD orally+CAP regular treatments

DRUG

SR1375 capsule 0.3mg+regular treatments

SR1375 capsule 0.3mg QD orally+CAP regular treatments

DRUG

Placebo capsule+regular treatments

Placebo capsule QD orally+CAP regular treatments

Sponsors & Collaborators

  • Shanghai SIMR Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Weimin Li, MD · West China Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-10
Primary Completion
2025-10-15
Completion
2025-10-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06577558 on ClinicalTrials.gov